1-20 of 28
Joseph M. Tuscano
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome

Sunmin Park, Christopher Hannigan, Joseph M Tuscano, John Timmerman, Caspian H. Oliai
Journal: Blood
Blood (2023) 142 (Supplement 1): 4858.
https://doi.org/10.1182/blood-2023-183012
Published: 2023
Journal Articles

Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826

Sarah C. Rutherford, Hongli Li, Alex F. Herrera, Michael Leblanc, Sairah Ahmed, Kelly L. Davison, Carla Casulo, Nancy L. Bartlett, Joseph M Tuscano, Brian Hess, Pallawi Torka, Pankaj Kumar, Ryan W Jacobs, Joo Y Song, Sharon M. Castellino, Brad S. Kahl, John P. Leonard, Sonali M. Smith, Jonathan W. Friedberg, Andrew M Evens
Journal: Blood
Blood (2023) 142 (Supplement 1): 181.
https://doi.org/10.1182/blood-2023-180114
Published: 2023
Journal Articles

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Hun Ju Lee, Michael Y. Choi, Tanya Siddiqi, Joanna M. Rhodes, William G. Wierda, Iris Isufi, Joseph M Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori Leslie, Alec Goldenberg, Gina G Chung, James B. Breitmeyer, Salim Yazji, Michael Wang, Catriona Jamieson, Thomas J. Kipps
Journal: Blood
Blood (2022) 140 (Supplement 1): 566–568.
https://doi.org/10.1182/blood-2022-167153
Published: 2022
Journal Articles

A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

Tamer Othman, Christopher Ruel, Paul Frankel, Alexander A. Merleev, Guillaume Luxardi, Emanual Maverakis, Mehrdad Abedi, Raghuveer Ranganathan, Jasmine Zain, Lihua E Budde, Matthew Mei, Aaron S Rosenberg, Rasmus T Hoeg, Caitlin Costello, Francine M. Foss, Basem M. William, H. Kent Holland, Miguel Villalona-Calero, Elad Sharon, Joseph M Tuscano
Journal: Blood
Blood (2022) 140 (Supplement 1): 9446–9447.
https://doi.org/10.1182/blood-2022-167173
Published: 2022
Journal Articles

Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients

Michelle A. Quan, Kwan-Keat Ang, Joseph M Tuscano, Mehrdad Abedi, Brian A. Jonas, Naseem S Esteghamat, Jeanna L Welborn, Paul R. Kaesberg, Aaron S Rosenberg
Journal: Blood
Blood (2022) 140 (Supplement 1): 7203–7205.
https://doi.org/10.1182/blood-2022-162959
Published: 2022
Journal Articles

Healthcare Resource Utilization in Acute Myeloid Leukemia Treatments: Hypomethylating Agent + Venetoclax Vs. High Intensity Regimens

Margaret Li Krackeler, Benjamin Moskoff, Tamer Othman, Tali Azenkot, Ryan J. Beechinor, Aaron S Rosenberg, Naseem S Esteghamat, Rasmus T Hoeg, Joseph M Tuscano, Brian A. Jonas
Journal: Blood
Blood (2022) 140 (Supplement 1): 8926–8928.
https://doi.org/10.1182/blood-2022-167966
Published: 2022
Journal Articles

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

Brian A. Jonas, Jeanna L Welborn, Naseem S Esteghamat, Rasmus T Hoeg, Aaron S Rosenberg, Laura Molnar, Ashley Linh Dang-Chu, Susan L Stewart, Joseph M Tuscano
Journal: Blood
Blood (2022) 140 (Supplement 1): 6213–6214.
https://doi.org/10.1182/blood-2022-168126
Published: 2022
Journal Articles

Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records

Aaron S Rosenberg, Albert William Riedl, Michelle A. Quan, Kwan-Keat Ang, Joseph M Tuscano, Naseem S Esteghamat, Brian A. Jonas, John Graff, Matthew Renquist, Joseph Cawood, Jeanna L Welborn, Rasmus T Hoeg, Paul R. Kaesberg, Kent Anderson, Jason Y Adams, Theresa H.M. Keegan
Journal: Blood
Blood (2022) 140 (Supplement 1): 7929–7931.
https://doi.org/10.1182/blood-2022-165607
Published: 2022
Journal Articles

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano
Journal: Blood
Blood (2022) 140 (Supplement 1): 11954–11955.
https://doi.org/10.1182/blood-2022-164905
Published: 2022
Journal Articles

Interim Results from the First Clinical Study of CC-95251, an Anti-Signal Regulatory Protein-Alpha (SIRPα) Antibody, in Combination with Rituximab in Patients with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)

Paolo Strati, Eliza Hawkes, Nilanjan Ghosh, Joseph M. Tuscano, Quincy Chu, Mary Ann Anderson, Amar Patel, Michael R. Burgess, Kristen Hege, Sapna Chhagan, Sarandeep Boyanapalli, Tracey Day, Frank Shen, Amitkumar Mehta
Journal: Blood
Blood (2021) 138 (Supplement 1): 2493.
https://doi.org/10.1182/blood-2021-147292
Published: 2021
Journal Articles

Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma

Alex F. Herrera, Tamer Othman, Paul Frankel, Pamela Allen, Leslie L. Popplewell, Geoffrey Shouse, Tanya Siddiqi, Alexey V. Danilov, Nora Ruel, Shari Daniels, Lacolle Peters, Stella Khoo, Steven T. Rosen, Elad Sharon, Joseph M Tuscano
Journal: Blood
Blood (2021) 138 (Supplement 1): 1407.
https://doi.org/10.1182/blood-2021-151188
Published: 2021
Journal Articles

An Open-Label Phase II Trial of the Combination of Decitabine, SQ Bortezomib and Pegylated Liposomal Doxorubicin for the Treatment of Patients with Relapsed/Refractory Acute Myelogenous Leukemia

Laura A. Potter, Maria Galkin, Aaron S. Rosenberg, Rasmus T. Hoeg, Mehrdad Abedi, Joseph M. Tuscano, Brian A. Jonas
Journal: Blood
Blood (2021) 138 (Supplement 1): 2352.
https://doi.org/10.1182/blood-2021-147349
Published: 2021
Journal Articles

First-Line Treatment with R-CHOP Vs Dose-Adjusted R-EPOCH for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis

Tamer Othman, Juan Penaloza, Elizabeth A Brem, Lauren C. Pinter-Brown, Abinav Baweja, Matthew Hyun Joon Lee, Jane Ly, Jack Reid, Haifaa Abdulhaq, Daria Gaut, Caspian Oliai, Erin G. Reid, Joseph M Tuscano
Journal: Blood
Blood (2021) 138 (Supplement 1): 2509.
https://doi.org/10.1182/blood-2021-151374
Published: 2021
Journal Articles

A Phase I Study of Anti-ICOS Antibody MEDI-570 for Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Angioimmunoblastic T-Cell Lymphoma (AITL) (NCI-9930)

Julio C. Chavez, MD, Francine M. Foss, MD, Basem M. William, MDMRCP, Jonathan E Brammer, MD, Sonali M. Smith, MD, Anca Prica, MD, Jasmine M. Zain, MD, Joseph M Tuscano, MD, Martha Glenn, MD, Neha Mehta-Shah, MD, Ben X Wang, Stephanie Zantinge, Lisa Wang, Ling Zhang, MD, Anmarie Boutrin, Weiguang Zhao, Lily Cheng, Nathan Standifer, Gianluca Carlesso, Jeffrey Moscow, Lillian Siu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-136465
Published: 2020
Journal Articles

A Phase 1 Study of Everolimus and Bendamustine in Patients with Relapsed or Refractory Lymphoid Malignancies and Myeloma

Julian R Davis, MD MA, Brian A Jonas, MD PhD, Joseph M Tuscano, MD, Aaron Seth Rosenberg, MD, Mehrdad Abedi, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 4038.
https://doi.org/10.1182/blood.V130.Suppl_1.4038.4038
Published: 2017
Journal Articles

Effect of Autologous Hematopoietic Stem Cell Transplant (aHSCT) on the Development of Second Primary Malignancies (SPM) in Multiple Myeloma Patients

Aaron Seth Rosenberg, MD, Ann M Brunson, MS, Joseph M Tuscano, MD, Brian A Jonas, MD PhD, Mehrdad Abedi, MD, Ted Wun, MD FACP, FRCPA, Theresa H.M. Keegan, PhD MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 332.
https://doi.org/10.1182/blood.V130.Suppl_1.332.332
Published: 2017
Journal Articles

Intravenous, Intraperitoneal, and Subcutaneous Routes of Administering 64 Cu-DOTA-HB22.7 Display Equivalent Tumor Targeting Ability.

Shiloh M. Martin, MD, Robert T. O’Donnell, M.D., Hayes McKnight, Julie L. Sutcliff, PhD, Joseph M. Tuscano, M.D.
Journal: Blood
Blood (2007) 110 (11): 2359.
https://doi.org/10.1182/blood.V110.11.2359.2359
Published: 2007
Journal Articles

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Julie M. Vose, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Izidore S. Lossos, MD, Annette Ervin-Haynes, DO, Kenichi Takeshita, MD, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD
Journal: Blood
Blood (2007) 110 (11): 2570.
https://doi.org/10.1182/blood.V110.11.2570.2570
Published: 2007
Journal Articles

The CD22 Epitope, Dose, Dosing Interval, and Timing All Effect Efficacy of Anti-CD22 mAb-Based Therapy of NHL.

Robert O’Donnell, MD, David Pearson, PhD, Hayes McKnight, Thomas Tedder, PhD, Joseph M. Tuscano, MD
Journal: Blood
Blood (2007) 110 (11): 2355.
https://doi.org/10.1182/blood.V110.11.2355.2355
Published: 2007
Journal Articles

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

Joseph M. Tuscano, MD, Izidore S. Lossos, MD, Glen Justice, MD, Julie M. Vose, MD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD
Journal: Blood
Blood (2007) 110 (11): 2563.
https://doi.org/10.1182/blood.V110.11.2563.2563
Published: 2007